At a glance
ClinicalIndex Comparison RecordN/ACompleted· 216 enrolled
Drug / intervention
lopinavir/ritonavir +1 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
ProSpective, MultI-Center, Observational PrograM to Assess the Effectiveness of Dual TheraPy (Lopinavir/Ritonavir + LamivudinE) in Treatment-Experienced HIV Infected Patients in the Routine Clinical Settings of the Russian Federation (SIMPLE)
In Brief
An observational study evaluating lopinavir/ritonavir and lamivudine for HIV-1 Infection. Completed, enrolled 216 participants.
Detailed Summary
This study seeks to assess the virologic effectiveness of dual therapy (lopinavir/ ritonavir (LPV/r) + lamivudine (3TC)) in treatment-experienced human immunodeficiency virus 1 (HIV-1) infected participants with an undetectable plasma HIV-1 (ribonucleic acid) RNA level (for at least 6 months) at the 48 week time point of treatment in the routine clinical settings of the Russian Federation.
Study Details
Study Typeobservational
Allocation--
Masking--
Primary Purpose--
ConditionsHIV-1 Infection
Countries--
Collaborators--
Timeline
N/ACompletedFinished
20162017201820192020202120222023202420252026
First PostedOct 2015
Enrollment StartDec 2015
Primary CompletionMay 2017
TodayJul 2026
First PostedOct 20, 2015
Enrollment StartDec 21, 2015
Primary CompletionMay 27, 2017
TodayJul 2, 2026
Enrollment to primary: 1.4 yearsPosted 10.7 years ago
Interventions
lopinavir/ritonavirdrug
tablet
lamivudinedrug
tablet